Life Science Recruitment

Interesting take from Computerworld. When AI explains its reasoning to a human, people tend to stop second-guessing it. Worth thinking about for anyone building or working with AI systems.

When AI explains its decision, humans may stop thinking independently Researchers found that adding LLM-generated rationales to recommendations can suppress productive human disagreement and cause evaluators to reject high-potential ideas.

Good read on what is happening in Ireland's regulatory pharma space right now. Both the challenges and the opportunities for professionals working in that environment.

Challenge and opportunity in Ireland’s regulatory pharma space Suzanne Keating, a regulatory affairs senior director at Viatris, explores Ireland's regulatory pharma space and the skills needed to succeed.

EU rules should make it easier for medical-device companies to plan product launches!

EU change ‘to help medical-device firms’ We use cookies to collect and analyse information on site performance and usage to improve and customise your experience, where applicable. View our Cookies Policy. Click Accept and continue to use our website or Manage to review and update your preferences.

"Medtronic has won an expanded CE mark indication for its Affera mapping and ablation system with Sphere-9 catheter to treat ventricular arrhythmias"

Medtronic wins expanded indication in Europe for Affera to treat VT Medtronic has won an expanded CE mark indication for its Affera mapping and ablation system with Sphere-9 catheter to treat ventricular arrhythmias.

"Ireland has built one of Europe’s strongest research and innovation ecosystems, with collaboration between universities and industry becoming an increasingly important competitive advantage. Those partnerships are helping to attract foreign direct investment, accelerate commercial innovation and develop the talent needed for emerging technologies."

Global tech race boosts pipeline of industry-experienced researchers Highly skilled, talented researchers are Ireland’s critical asset

Collaboration between Research Ireland’s Rinn Pharma & Biopharma (RP&B) and Cork-based biotech spin-out ArrayPatch will focus on developing a novel skin cancer treatment using a patented dissolvable microneedle platform.

Rinn centre and ArrayPatch to partner on skin cancer treatment Rinn Pharma & Biopharma and Cork's ArrayPatch are building a novel skin cancer treatment using a patented dissolvable microneedle platform.

"OpenAI will add 250 new roles across GTM (go to market / sales), engineering, user operations, human resources, finance, privacy, legal, corpsec and workplace. "

OpenAI announces new EU HQ and 250 additional jobs in Ireland OpenAI will create 250 jobs and establish its new EU headquarters in Dublin, further expanding its Irish operations.

Collaboration continues to fuel innovation in advanced therapies. EpilepsyGTx and ClearPoint Neuro have partnered to support a first-in-human gene therapy trial for epilepsy. Another exciting example of how collaboration is advancing treatments for neurological diseases.

EpilepsyGTx and ClearPoint Neuro join forces on targeted therapy - PharmaTimes Partnership to support first‑in‑human trial of EPY201 in epilepsy

A significant step forward in global health. Takeda's QDENGA has become the first dengue vaccine approved in India, marking an important step in tackling one of the world's fastest-growing mosquito-borne diseases. This approval highlights the continued impact of pharmaceutical innovation in improving public health and expanding access to life-saving vaccines.

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India Takeda Pharmaceutical's dengue vaccine Qdenga has been approved by India's drug regulator, making it the first such vaccine to be cleared in the country, the Japanese drugmaker's ​India unit said on Monday.

Positive news for patients living with IgA nephropathy. The FDA has granted full approval to Novartis' Fabhalta, marking another important advancement in kidney disease treatment. The decision reflects continued innovation in nephrology and highlights the strength of today's pharmaceutical pipeline.

Novartis gains full FDA nod for Fabhalta in kidney disorder IgAN With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, Novartis is on its way to cornering the market for the indication. | The FDA has converted its accelerated approval for Novartis' Fabhalta into a full blessing to treat patients w...